Veloxis Pharmaceuticals Completes Enrolment in LCP-Tacro™ 3002 Pivotal Phase ... Sacramento Bee The primary endpoint of the study, a composite endpoint (BPAR (Biopsy Proven Acute Rejection), graft failure, loss to follow up or death), will be evaluated after a 12-month treatment period to demonstrate the non-inferiority of LCP-Tacro compared to ... |
